Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
lasofoxifene · 4 trials · 2 indications
Lumbar Spine Bome Mineral Density
Percent change from baseline in lumbar spine BMD at Month 12
| Arm | Type | Description |
|---|---|---|
| Lasofoxifene 0.25 mg | EXPERIMENTAL | lasofoxifene 0.25 mg/day |
| raloxifene | ACTIVE_COMPARATOR | raloxifene 60 mg/day |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| lasofoxifene 0.5 mg/day | EXPERIMENTAL | - |
| lasofoxifene 0.25 mg/day | EXPERIMENTAL | - |
| Lasofoxifene 0.25 mg/d | EXPERIMENTAL | - |
| Lasofoxifene Dose 1 | EXPERIMENTAL | 0.05 mg |
| Lasofoxifene Dose 2 | EXPERIMENTAL | 0.25 mg |
| Lasofoxifene Dose 3 | EXPERIMENTAL | 0.5 mg |
| Name | Type | Description |
|---|---|---|
| lasofoxifene | DRUG | lasofoxifene 0.25mg |
| raloxifene | DRUG | raloxifene 60 mg/day |
| Placebo | DRUG | 0 mg/day |
Inclusion Criteria: * Postmenopausal women with low bone density (osteopenia) and screening labs, pelvic ultrasound, mammogram without significant findings Exclusion Criteria: * Presence of metabolic bone disease, fractures, blood clots, or recent cancer. * Any use of selective estrogen receptor ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Precision BioSciences, Inc. | DTIL | 1 | N/A | Undisclosed |
| SI-BONE, Inc. | SIBN | 1 | - | Undisclosed |
Lasofoxifene is an investigational small molecule being developed for osteoporosis and bone loss in postmenopausal women. It is in Phase 2 clinical development and has not been approved by the FDA. The drug is being studied for its effects on bone density and fracture risk reduction.
Lasofoxifene is being developed by Ligand Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol LGND. The company is conducting clinical trials to evaluate the drug's safety and efficacy in postmenopausal women with osteoporosis and bone loss.
Lasofoxifene is currently in Phase 2 clinical development. While some completed trials were Phase 3, the drug's overall development status is Phase 2, meaning it is still investigational and not yet approved for commercial use. All three completed trials have finished, with no active trials currently ongoing.
Lasofoxifene has been studied in three completed clinical trials. The largest, NCT00141323, was a Phase 3 study in 8,556 postmenopausal women with osteoporosis. NCT00143273 was a Phase 2 dose-response study in 497 Japanese and Asian women. NCT00163137 compared lasofoxifene to raloxifene and placebo in 540 women.
No, Lasofoxifene is not the same as raloxifene, though both are selective estrogen receptor modulators studied for osteoporosis. A completed Phase 3 trial (NCT00163137) directly compared lasofoxifene, raloxifene, and placebo on bone loss in postmenopausal women, indicating they are distinct drugs being evaluated for similar use.